SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gibson P, Rosella O. Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease. Gut 1995; 37:53643.
  • 2
    Arai F, Takahashi T, Furukawa K et al. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn’s disease. Dig Dis Sci 1998; 43:20719.
  • 3
    MacDermott RP, Sanderson IR, Reinecker HC. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 1998; 4:5467.
  • 4
    Keshavarzian A, Fusunyan RD, Jacyno M et al. Increased interleukin-8 in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. Am J Gastroenterol 1999; 94:70412.
    Direct Link:
  • 5
    Stevens C, Walz G, Singaram C et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37:81826.
  • 6
    Dionne S, Hiscott J, D’Agata I et al. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997; 42:155766.
  • 7
    Casini-Raggi V, Kam L, Chong YJ et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154:243440.
  • 8
    Troncone R, Caputo N, Campanozzi A et al. Gut lavage IgG and interleukin 1 receptor antagonist: interleukin 1 beta ratio as markers of intestinal inflammation in children with inflammatory bowel disease. Gut 1997; 41:605.
  • 9
    Yang SK, Eckmann L, Panja A et al. Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. Gastroenterology 1997; 113:121423.
  • 10
    Jung HC, Eckmann L, Yang SK et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 1995; 95:5565.
  • 11
    Eckmann L, Jung HC, Schurer-Maly C et al. Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of interleukin 8. Gastroenterology 1993; 105:168997.
  • 12
    Yu Y, Chadee K. Entamoeba histolytica stimulates interleukin 8 from human colonic epithelial cells without parasite-enterocyte contact. Gastroenterology 1997; 112:153647.
  • 13
    Li CK, Seth R, Gray T et al. Production of proinflammatory cytokines and inflammatory mediators in human intestinal epithelial cells after invasion by Trichinella spiralis. Infect Immun 1998; 66:22006.
  • 14
    Bjorck S, Jennische E, Dahlstrom A et al. Influence of topical rectal application of drugs on dextran sulfate-induced colitis in rats. Dig Dis Sci 1997; 42:82432.
  • 15
    McCafferty DM, Sharkey KA, Wallace JL. Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol 1994; 266:G5607.
  • 16
    Arlander E, Ost A, Stahlberg D et al. Ropivacaine gel in active distal ulcerative colitis and proctitis – a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 1996; 10:7381.
  • 17
    Giddon DB, Lindhe J. In vivo quantitation of local anesthetic suppression of leukocyte adherence. Am J Pathol 1972; 68:32738.
  • 18
    MacGregor RR, Thorner RE, Wright DM. Lidocaine inhibits granulocyte adherence and prevents granulocyte delivery to inflammatory sites. Blood 1980; 56:2039.
  • 19
    Martinsson T, Oda T, Fernvik E et al. Ropivacaine inhibits leukocyte rolling, adhesion and CD11b/CD18 expression. J Pharmacol Exp Ther 1997; 283:5965.
  • 20
    Goldstein IM, Lind S, Hoffstein S et al. Influence of local anesthetics upon human polymorphonuclear leukocyte function in vitro. Reduction of lysosomal enzyme release and superoxide anion production. J Exp Med 1977; 146:48394.
  • 21
    Irita K, Fujita I, Takeshige K et al. Cinchocaine and amethocaine inhibit activation and activity of superoxide production in human neutrophils. Br J Anaesth 1986; 58:63945.
  • 22
    Martinsson T, Haegerstrand A, Dalsgaard CJ. Effects of ropivacaine on eicosanoid release from human granulocytes and endothelial cells in vitro. Inflamm Res 1997; 46:398403.DOI: 10.1007/s000110050210
  • 23
    Sinclair R, Eriksson AS, Gretzer C et al. Inhibitory effects of amide local anaesthetics on stimulus-induced human leukocyte metabolic activation, LTB4 release and IL-1 secretion in vitro. Acta Anaesthesiol Scand 1993; 37:15965.
  • 24
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65:5563.
  • 25
    Dickstein R, Kiremidjian-Schumacher L, Stotzky G. Effects of lidocaine on the function of immunocompetent cells. I. In vitro exposure of mouse spleen lymphocytes and peritoneal macrophages. Immunopharmacology 1985; 9:11725.
  • 26
    Vannier E, De Waal M, Salazar-Montes A et al. Interleukin-13 induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein. Blood 1996; 87:330715.
  • 27
    Fugh LS. The chemistry and pharmacology of local anaesthetics. CRNA 1993; 4:1619.
  • 28
    Moudgil GC, Allan RB, Russell RJ et al. Inhibition, by anaesthetic agents, of human leucocyte locomotion towards chemical attractants. Br J Anaesth 1977; 49:97105.
  • 29
    Taniguchi T, Shibata K, Yamamoto K et al. Effects of lidocaine administration on hemodynamics and cytokine responses to endotoxemia in rabbits. Crit Care Med 2000; 28:7559.
  • 30
    Madara JL, Stafford J. Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 1989; 83:7247.
  • 31
    Chavez AM, Menconi MJ, Hodin RA et al. Cytokine-induced intestinal epithelial hyperpermeability: role of nitric oxide. Crit Care Med 1999; 27:224651.
  • 32
    Sun Z, Wang X, Lasson A et al. Roles of platelet-activating factor, interleukin-1beta and interleukin-6 in intestinal barrier dysfunction induced by mesenteric arterial ischemia and reperfusion. J Surg Res 1999; 87:90100.
  • 33
    Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095147.
  • 34
    Horai R, Saijo S, Tanioka H et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191:31320.
  • 35
    Nicklin MJ, Hughes DE, Barton JL et al. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000; 191:30312.
  • 36
    Cunnane G, Madigan A, Murphy E et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology 2001; 40:629.
  • 37
    Haskill S, Martin G, Van Le L et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA 1991; 88:36815.
  • 38
    Daig R, Rogler G, Aschenbrenner E et al. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 2000; 46:3508.
  • 39
    Butcher C, Steinkasserer A, Tejura S et al. Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. J Immunol 1994; 153:70111.
  • 40
    Dinarello CA. Induction of interleukin-1 and interleukin-1 receptor antagonist. Semin Oncol 1997; 24:S9–S9.
  • 41
    Sciacca FL, Canal N, Edoardo GL. Induction of IL-1 receptor antagonist by interferon beta: implication for the treatment of multiple sclerosis. J Neurovirol 2000; 6 (Suppl.):S33S37.
  • 42
    Chantry D, Turner M, Abney E et al. Modulation of cytokine production by transforming growth factor-beta. J Immunol 1989; 142:4295300.